My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Qiagen N.V. Common Shares (NY:QGEN)

45.22 -0.22 (-0.48%)

Official Closing Price Updated: 7:00 PM EST, Dec 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 Next >

Qiagen (QGEN) Q3 2025 Earnings Call Transcript ↗

November 05, 2025

Qiagen (QGEN) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings World Trade

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

QIAGEN N.V. (NYSE:QGEN) Passes the Caviar Cruise Quality Investment Screen ↗

October 18, 2025

QIAGEN NV exemplifies the Caviar Cruise investing method with strong sales growth, a 46% ROIC, and robust cash flow, signaling a high-quality business.

Via Chartmill

Illumina's BioInsight Launch Sparks Optimism, Signals New Era for Genomic Data and AI

October 01, 2025

San Diego, CA – October 1, 2025 – Illumina, Inc. (NASDAQ: ILMN) saw its shares surge by 6.6% today following the announcement and immediate launch of its new business unit, BioInsight. This strategic...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

A Look at Qiagen's Upcoming Earnings Report ↗

August 04, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Qiagen Earnings Review: Q4 Summary ↗

February 05, 2025

Via Benzinga

Qiagen: Q4 Earnings Insights ↗

February 05, 2025

Via Benzinga

DoorDash To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday ↗

August 07, 2025

Via Benzinga

QIAGEN N.V. (NYSE:QGEN) - A Strong Technical Setup for Breakout Investors ↗

July 21, 2025

QIAGEN N.V. (NYSE:QGEN) shows strong technicals and a high-quality breakout setup, making it a candidate for momentum traders. The stock trades near 52-week highs with clear support and resistance...

Via Chartmill

QIAGEN N.V. (NYSE:QGEN) – A Quality Stock Worth Considering ↗

June 26, 2025

QIAGEN N.V. (NYSE:QGEN) is a quality stock with strong revenue growth, high ROIC, and solid cash flow conversion, making it a candidate for long-term investors.

Via Chartmill

Retail Investors Flock To Incyte As Drug Data, Qiagen Deal Fuel Optimism ↗

June 16, 2025

Stifel also upgraded the stock to ‘Buy’ with a $107 price target.

Via Stocktwits

QIAGEN N.V. (NYSE:QGEN) – A Quality Stock with Strong Fundamentals ↗

June 02, 2025

QIAGEN N.V. (NYSE:QGEN) is a quality stock with strong revenue growth, high ROIC, and solid financial health, making it a candidate for long-term investors.

Via Chartmill

Earnings Scheduled For February 5, 2025 ↗

February 05, 2025

Via Benzinga

Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week ↗

April 29, 2024

With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.

Via Benzinga

Topics Stocks

Earnings Scheduled For February 6, 2024 ↗

February 06, 2024

Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion.

Via Benzinga

Earnings Preview: Qiagen ↗

February 05, 2024

Via Benzinga

Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance ↗

April 07, 2025

Qiagen (QGEN) shares up premarket after disclosing strong preliminary Q1 2025 results and raising full-year EPS outlook. Stock price up 3.06%.

Via Benzinga

2 Recent Stock Splits You've Never Heard of That Certain Wall Street Analysts Think Could Soar 39% and 62% ↗

February 23, 2025

Via The Motley Fool

This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

February 19, 2025

Via Benzinga

18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker' ↗

October 10, 2024

Goldman Sachs identifies 18 stocks for potential earnings upside and advises options-based strategies in a volatile market. 10% upside for S&P 500.

Via Benzinga

Topics Stocks

FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation ↗

June 24, 2024

The FDA granted accelerated approval to Bristol Myers Squibb's Krazati (adagrasib) with cetuximab for adult patients with KRASG12C-mutated advanced or metastatic colorectal cancer.

Via Benzinga

Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

June 20, 2024

Via Benzinga

Qiagen Unveils Plan For $1B Shareholder Returns, Major Product Launches ↗

June 17, 2024

QIAGEN announces a comprehensive growth strategy by 2028. The plan includes significant shareholder returns, new product launches, and a focus on digital and diagnostic advancements.

Via Benzinga

QGEN Stock Earnings: Qiagen Beats EPS, Beats Revenue for Q1 2024 ↗

April 29, 2024

QGEN stock results show that Qiagen beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

US Stocks Set To Approach New Week With Caution Ahead Of Fed Meeting, Tech Earnings: Analyst Says 'Buy The Dip' Contingent On This Condition ↗

April 29, 2024

U.S. stocks are looking to build on past week’s gains, with the mood remaining cautiously optimistic. The major index futures were modestly higher in early trading.

Via Benzinga

Topics Economy

Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report ↗

May 06, 2024

According to FactSet, a financial data analytics firm, 80% of S&P 500 companies have reported earnings so far.

Via Benzinga

Topics Stocks

US Stocks Kick Off The Week In The Green, Tesla Rockets On China's FSD Approval, Yen Rallies: What's Driving Markets Monday? ↗

April 29, 2024

U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events including earnings reports from tech giants like Amazon.com Inc....

Via Benzinga

Goldman Sachs Upgrades Twist Bioscience, Says Express Genes Launch Will Drive Margin Expansion ↗

January 17, 2024

Goldman Sachs upgrades Twist Bioscience as Express Genes launch addresses SynBio division's gross margin issues. With 5-7 days gene delivery, TWST taps into a previously inaccessible market, enhancing...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.